GlassScriptPhysician profile
Jaime Gonzalez
NPI 1477848695
$5,924.80
in general payments reported to CMS, 2019-2025
34 companies · $1,131 in 2025
The $1,131 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $281 · 2021: $506 · 2022: $2,331 · 2023: $676 · 2024: $768 · 2025: $1,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,366 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,366.14 |
| Education | $208.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,665.52 | 2022 | |
| Vifor Pharma, INC. | $652.52 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $446.42 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $424.45 | 2020-2025 | Farxiga, Lokelma |
| Amgen INC. | $412.74 | 2019-2025 | Krystexxa, Tavneos |
| Opko Pharmaceuticals, LLC | $356.37 | 2020-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $311.66 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $223.46 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $158.08 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.86 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $138.33 | 2025 | Ozempic, Wegovy |
| Viiv Healthcare Company | $116.96 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $108.27 | 2021-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $99.31 | 2024 | |
| Akebia Therapeutics INC | $96.50 | 2019-2024 | Auryxia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $91.87 | 2022-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $76.54 | 2023-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $73.00 | 2019-2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $67.48 | 2024-2025 | Acthar |
| Xeris Pharmaceuticals, INC. | $60.02 | 2024 | Gvoke Hypopen |
| Cardiovascular Systems INC. | $50.71 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $26.14 | 2024 | |
| Lilly USA, LLC | $21.71 | 2025 | Zepbound |
| E.R. Squibb & Sons, L.L.C. | $17.41 | 2023 | |
| Pfizer INC. | $16.63 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $15.79 | 2021 | |
| Horizon Therapeutics Plc | $14.89 | 2023 | Krystexxa |
| Scpharmaceuticals INC. | $14.89 | 2025 | |
| Shire North American Group INC | $14.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.96 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.